R
Richard P. Beckmann
Researcher at Eli Lilly and Company
Publications - 55
Citations - 2677
Richard P. Beckmann is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Cancer & Kinase. The author has an hindex of 22, co-authored 53 publications receiving 2105 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik,Lee S. Rosen,Sara M. Tolaney,Anthony W. Tolcher,Jonathan W. Goldman,Leena Gandhi,Kyriakos P. Papadopoulos,Muralidhar Beeram,Drew W. Rasco,John Hilton,Aejaz Nasir,Richard P. Beckmann,Andrew E. Schade,Angie D. Fulford,Tuan S. Nguyen,Ricardo Martinez,Palaniappan Kulanthaivel,Lily Q. Li,Martin Frenzel,Damien M. Cronier,Edward M. Chan,Keith T. Flaherty,Patrick Y. Wen,Geoffrey I. Shapiro +23 more
TL;DR: Abemaciclib represents the first selective inhibitor of CDK4 and CDK6 with a safety profile allowing continuous dosing to achieve sustained target inhibition, and this first-in-human experience demonstrates single-agent activity for patients with advanced breast cancer, NSCLC, and other solid tumors.
Journal ArticleDOI
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
David Schaer,Richard P. Beckmann,Jack A. Dempsey,Lysiane Huber,Amelie Forest,Nelusha Amaladas,Yanxia Li,Ying Cindy Wang,Erik R. Rasmussen,Darin Chin,Andrew Capen,Carmine Carpenito,Kirk A. Staschke,Linda A. Chung,Lacey M. Litchfield,Farhana F. Merzoug,Xueqian Gong,Philip W. Iversen,Sean Buchanan,Alfonso De Dios,Ruslan D. Novosiadly,Michael Kalos +21 more
TL;DR: Data from murine syngeneic tumor models and in vitro assays support the clinical investigation of the combination of abemaciclib with agents such as anti-PD-L1 that modulate T cell anti-tumor immunity.
Journal ArticleDOI
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
Xueqian Gong,Lacey M. Litchfield,Yue Webster,Li-Chun Chio,Swee Seong Wong,Trent R. Stewart,Michele Dowless,Jack A. Dempsey,Yi Zeng,Raquel Torres,Karsten Boehnke,Cecilia Mur,Carlos Marugán,Carmen Baquero,Chunping Yu,Steven M. Bray,Isabella H. Wulur,Chen Bi,Shaoyou Chu,Hui-Rong Qian,Philip W. Iversen,Farhana F. Merzoug,Xiang S. Ye,Christoph Reinhard,Alfonso De Dios,Jian Du,Charles W. Caldwell,Maria Jose Lallena,Richard P. Beckmann,Sean Buchanan +29 more
TL;DR: A subset of cancers highly sensitive to CDK4/6 inhibition is reported and characterized by various genomic aberrations known to elevate D-cyclin levels and a recurrent CCND1 3'UTR mutation associated with increased expression in endometrial cancer is described.
Journal ArticleDOI
CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.
TL;DR: This review is intended to provide information on the current progress of CHK1 inhibitors in pre-clinical and clinical development and will focus on mechanisms of single-agent activity and potential strategies for patient tailoring and combinations with non-genotoxic agents.
Journal ArticleDOI
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
Constance King,H. Bruce Diaz,Samuel McNeely,Darlene S. Barnard,Jack A. Dempsey,Wayne Blosser,Richard P. Beckmann,David Anthony Barda,Mark S. Marshall +8 more
TL;DR: The characterization of a novel CHK1 inhibitor, LY2606368, which as a single agent causes double-stranded DNA breakage while simultaneously removing the protection of the DNA damage checkpoints is described, suggesting replication catastrophe as the mechanism of DNA damage.